Prospective Evaluation Of Delayed Effects Of Pediatric Car T Cell Therapy

Launched by ST. JUDE CHILDREN'S RESEARCH HOSPITAL · Aug 28, 2024

Keywords

ClinConnect Summary

This clinical trial is looking to understand the short-term and long-term side effects of CAR-T cell therapy in young patients with certain types of blood cancers and solid tumors. Researchers want to learn more about how often patients experience infections, delays in their blood cell recovery, or any damage to their nervous system after receiving this treatment.

To be eligible for the trial, participants need to be 30 years old or younger and must have received their first CAR-T cell therapy infusion within the last 1 to 3 months. The study is not currently recruiting participants, so no one can join just yet. If you or someone you know is considering taking part in this trial, it's important to understand that you'll be monitored closely for any side effects related to the therapy, helping to improve our understanding of how CAR-T cell therapy affects young patients over time.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Participants must have received an initial systemically-administered CAR T cell infusion within the last 1-3 months (+/- 14 days).
• • Initial infusion is defined as the first administration of a CAR T cell product the participant has not previously received OR receipt of a CAR T cell product previously received after an interval allogeneic HSCT.
• • Age ≤ 30 years at CAR T cell infusion.
• Exclusion Criteria:
• • Active malignancy other than the disease under study.
• • Planned consolidative HSCT within 3 months post CAR T cell infusion.
• • Received or planned additional disease directed therapy post CAR T cell infusion.
• • Inability or unwillingness of research participant or legal guardian/representative to give written informed consent.